Researchers Develop Promising Treatment for Brain Disorders

NYU Abu Dhabi and University of Denver team identify small molecule that could slow Parkinson's progression

Apr. 2, 2026 at 2:31pm

Got story updates? Submit your updates here. ›

A team of researchers from NYU Abu Dhabi and the University of Denver has identified a small molecule called SK-129 that could help slow or halt the progression of serious brain diseases like Parkinson's. The molecule works by preventing the buildup and spread of harmful proteins in the brain, and has shown promising results in human cells, patient-derived tissue, and animal models.

Why it matters

Current treatments for neurodegenerative brain disorders like Parkinson's only manage symptoms, but do not address the underlying causes. This new small molecule represents a potential breakthrough in developing treatments that can actually slow or stop the disease process itself, offering new hope for patients.

The details

The researchers, led by Mazin Magzoub from NYU Abu Dhabi and Rajesh Kumar from the University of Denver, developed SK-129 to block the harmful clumping and spreading of disease-related proteins in the brain. They tested the molecule across a range of models, including human cells, patient samples, and mouse studies, and found it was able to significantly reduce the development of disease-related brain damage.

  • The study was published in Science Translational Medicine on April 2, 2026.

The players

Mazin Magzoub

Associate Professor of Biology at NYU Abu Dhabi and co-lead author of the study.

Rajesh Kumar

Researcher at the University of Denver and co-lead author of the study.

NYU Abu Dhabi

A research university located in Abu Dhabi, United Arab Emirates, where part of the study was conducted.

University of Denver

A private research university located in Denver, Colorado, where part of the study was conducted.

Got photos? Submit your photos here. ›

What they’re saying

“This is an important step toward developing treatments that target the root cause of these diseases. Instead of only treating symptoms, we are working toward slowing or stopping the disease itself.”

— Mazin Magzoub, Associate Professor of Biology, NYU Abu Dhabi

What’s next

The researchers plan to continue testing SK-129 in additional animal models and work towards clinical trials to evaluate its safety and efficacy in human patients.

The takeaway

This breakthrough research offers new hope for patients suffering from debilitating neurodegenerative brain disorders like Parkinson's, as the development of a treatment that can slow or halt disease progression would be a major advancement beyond current symptom-management therapies.